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Statement of findings
We have analyzed the pattern of procoagulant and fibrinolytic gene expression in affected
joints during the course of arthritis in two murine models. In both models, we found an
increased expression of tissue factor, tissue factor pathway inhibitor, urokinase plasminogen
activator, and plasminogen activator inhibitor 1, as well as thrombin receptor. The observed
pattern of gene expression tended to favor procoagulant activity, and this pattern was
confirmed by functional assays. These alterations would account for persistence of fibrin
within the inflamed joint, as is seen in rheumatoid arthritis.
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AIA = antigen-induced arthritis; CIA = collagen-induced arthritis; EGR1 = early growth response gene 1; GAPDH = glyceraldehyde-3-phosphate
dehydrogenase; NF-kB = nuclear factor kB; PAI-1, PAI1 = plasminogen activator inhibitor 1 (protein and gene, respectively); PAR-1, PAR1 = pro-
tease-activated receptor 1 (protein and gene, respectively); PBS = phosphate-buffered saline (solution); PCA = procoagulant activity; RA =
rheumatoid arthritis; RPA = RNase protection assay; TAT = thrombin–antithrombin III complex; TF, TF = tissue factor (protein and gene, respec-
tively); TFPI, TFPI = tissue factor pathway inhibitor (protein and gene, respectively); uPA, UPA = urokinase plasminogen activator (protein and gene,
respectively); VEGF, VEGF = vascular endothelial growth factor (protein and gene, respectively).
Introduction: Accumulation of fibrin in the joints remains one of
the most striking histopathological features of rheumatoid
arthritis (RA). Recently, we have provided evidence of the
deleterious role of synovial fibrin deposition in arthritic joints in
antigen-induced arthritis (AIA), a well-established murine model
of RA.
A local imbalance between fibrin formation and fibrin
dissolution may result in fibrin deposition in the joints.
On the one hand, fibrin formation is mainly initiated by tissue
factor (TF), a transmembrane protein serving as a receptor for
factor VII. Under normal conditions, TF expression and activity
are tightly regulated. Constitutive TF expression is restricted to
perivascular and epithelial cells, and the catalytic activity of the
TF/VIIa complex can be inhibited by tissue factor pathway
inhibitor (TFPI). Pathological conditions can perturb the cell-
type-restricted pattern of TF expression. In particular, recent
reports have shown that transcriptional activation of TF can be
mediated by molecular mechanisms involving induction of the
early growth response gene 1 (EGR1) or of the protease-
activated receptor (PAR1) or vascular endothelial growth factor
(VEGF) genes.
On the other hand, fibrin degradation is mediated primarily by
plasmin, which is the active form of the zymogen plasminogen.
Conversion of plasminogen to plasmin is under the control of
serine protease plasminogen activators, such as the urokinase
plasminogen activator (uPA), and their inhibitors, such as the
plasminogen activator inhibitor (PAI-1).
Aims: We hypothesized that the deposition of fibrin in the
joints may result from an imbalance in the local expression of
key genes involved in coagulation and fibrinolytic pathways. To
test this hypothesis, we investigated mRNA levels in arthritic
versus nonarthritic joint tissues from two murine models of RA:
http://arthritis-research.com/content/2/6/504http://arthritis-research.com/content/2/6/504
Introduction
Rheumatoid arthritis (RA) is a common autoimmune
disease of unknown etiology, characterized by chronic syn-
ovial inflammation that leads to progressive destruction of
cartilage and bone [1]. Immunological mechanisms are
thought to initiate synovial inflammation, which becomes
persistent with the disease progression. Among the many
histopathological features described, one of the most strik-
ing is the accumulation of fibrin [2,3]. We have recently
provided evidence that synovial deposition of this protein
plays a deleterious role in arthritic joints in antigen-induced
arthritis (AIA), a well-established model of RA [4]. This
accumulation of fibrin could result from a local imbalance
between its formation and dissolution. Previous studies
have revealed enhanced coagulation activity in rheumatoid
synovial fluid and membrane [3,5] as well as increased
activity of synovial urokinase plasminogen activator (uPA) in
rheumatoid synovial membrane [6]. Little is known about
the expression of procoagulant molecules in the arthritic
synovial membrane, and the molecular events that tip the
natural balance between synovial procoagulant and fibrinol-
ysis in favor of coagulation remain to be elucidated.
Synovial fibrin deposition is mediated principally by tissue
factor (TF), an activator of the extrinsic pathway of coagu-
lation. TF is a transmembrane protein that initiates coagu-
lation by serving as a cofactor for activated factor VII [7].
TF is constitutively expressed in perivascular and epithelial
cells, but its expression can be induced on endothelial
cells and monocytes by inflammation [8] and hypoxia [9].
Increased expression of TF during hypoxia is mediated by
the transcription factor early growth response gene 1
(EGR1) product and leads to pulmonary fibrin deposition
[9]. Tissue factor pathway inhibitor (TFPI), a naturally
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AIA and collagen-induced arthritis (CIA). Genes that are
directly implicated in coagulation (TF, TFPI) and fibrinolysis
(UPA,  PAI1), and other genes that may influence the
expression of TF (EGR1,  PAR1,  VEGF), were investigated
using a novel multiprobe RNase protection assay (RPA).
Furthermore, we evaluated coagulation activity in arthritic and
nonarthritic mice.
Methods: Mice with AIA or CIA were sacrificed at different
time points: 2, 4, and 16 h and 3, 7, and 14 d after intra-
articular antigen injection for AIA; 42 d after the first
immunization for CIA. Total RNA was prepared from arthritic
and nonarthritic knees for AIA, or arthritic and nonarthritic hind
paws for CIA. Messenger RNA (mRNA) levels of the genes
described above were determined by RPA and normalized to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA
levels. Coagulation assays were performed on joint tissue
extracts and concentrations of thrombin–antithrombin III (TAT)
complex were measured in plasma.
Results: In AIA, all the genes studied except VEGF were
upmodulated as early as 2 h. PAR1, TFPI, EGR1, and UPA
expression decreased to control levels by 16 h, whereas the
expression of TF and PAI1 remained elevated. At later times,
only TF, PAI1, and UPA showed sustained overexpression. In
CIA, gene expression was assayed at only one time point (42 d
after immunization) and all genes showed higher mRNA levels
in the affected paws than in control paws. In AIA mice,
procoagulant activity and TF activity were significantly
increased in arthritic joints, and in CIA mice, plasma TAT levels
were significantly enhanced.
Discussion: Fibrin deposition in synovia is prominent in both RA
and experimental arthritis, suggesting that this protein may play
a role in the pathogenesis of chronic inflammation. In this study,
we have tried to shed some light on the molecular mechanisms
leading to extravascular fibrin deposition, using two well-
established mouse models of RA: AIA and CIA. The kinetics of
gene expression was first analyzed in mice with AIA, because
this model allows for an accurate, temporally controlled
sampling of synovial inflammation. We then extended our
observations by analyzing one time point in CIA, 42 d after
immunization, when chronic inflammation is present. We found
that in both models, coagulation and fibrinolysis in arthritic joints
were significantly increased, and that the most significant
increases were in TF and PAI-1.
Although the molecular mechanism or mechanisms responsible
for the transcriptional changes observed are not completely
understood, the increases in TF, PAI-1, and uPA are probably
due to the production of proinflammatory cytokines such as
IL-1 and TGF-a. These cytokines, whose presence in the
inflamed synovium is well documented, are known to induce
these genes through the activation of nuclear factor kB
(NF-kB), a transcription factor. TF induction is also under the
control of a proximal enhancer containing a binding site for the
inducible transcription factor EGR1. Indeed, the early rise of
EGR1 expression in AIA is consistent with its classification as
immediate-early gene and may be responsible for the induction
of early expression of TF. Early TF stimulation in AIA can also
be accounted for by the transient overexpression of PAR1.
Contrary to what has been shown in RA, VEGF expression
remained essentially unchanged throughout the progression of
AIA, probably reflecting a peculiarity of this murine model.
The alteration of the patterns of gene expression was
accompanied by increased functional coagulation activity,
which was more marked in AIA than in CIA.
Conclusion: Prominent fibrin deposition in two different animal
models of RA – AIA and CIA – can be attributed to modulations
in key regulatory genes for coagulation and fibrinolysis.Arthritis Research    Vol 2 No 6 Salvi et al
occuring Kunitz-type inhibitor, regulates coagulation by
inhibiting the catalytic activity of the TF/VIIa complex [10].
Although little is known about its role in pathological
processes, by virtue of its anticoagulant effect, under- or
over-expression of this gene could alter the procoagulant/
anticoagulant balance.
Besides modulating fibrin deposition, activation of the
coagulation pathway can also modulate genes that play an
accessory role in inflammation by mediating cellular activa-
tion, for example thrombin receptor, protease-activated
receptor 1 (PAR-1), and vascular endothelial growth factor
(VEGF). PAR-1 is a G-protein-coupled receptor that binds
thrombin [11] and is abundantly expressed in inflamed
rheumatoid synovia [12]. Activation of PAR1 by thrombin
can lead to proliferation of synovial fibroblasts and rapidly
induces the transcription of TF mRNA [13]. Since PAR1
mRNA is itself upregulated by thrombin [14], PAR1 may
be part of a positive-feedback loop that potentiates the
coagulation cascade. VEGF stimulates endothelial-cell
proliferation  in vitro and induces neovascularization in vivo
[15]. Significant amounts of antigenic VEGF have been
detected in synovial fluids and tissues from RA patients
[16], and VEGF mRNA is abundantly expressed in highly
vascularized areas of the RA synovial tissue [17]. A TF-
dependent production of VEGF by human fibroblasts in
response to activated factor VII binding has been reported
[18]. Conversely, VEGF can induce the expression of TF
[19] and of UPA [15], thereby influencing the coagula-
tion/fibrinolysis equilibrium.
Degradation of extravascular fibrin is primarily mediated by
plasmin, which is formed upon cleavage of plasminogen
by plasminogen activators [20]. This fibrin degradation is
supported by increased synovial uPA activity evidenced in
human and experimental arthritis and by the observation
that lack of uPA leads to increased fibrin deposition in the
joint [4]. The activity of uPA is regulated by plasminogen
activator inhibitors (PAIs), in particular PAI-1 [20]. Both
UPA and PAI1 expression are induced by cytokines that
are abundant within the inflamed joint. [21].
In this study, we have analyzed the modulation of the
mRNA levels of TF, TFPI, PAR1, EGR1, VEGF, UPA, and
PAI1 in the inflamed joint in two murine models of arthritis,
namely AIA and collagen-induced arthritis (CIA). These
two models recapitulate many features of RA, especially
fibrin deposition in arthritic joints (for AIA, see [4]; for CIA,
Marty et al, submitted). We have used a novel multiprobe
RNase protection assay that was developed to facilitate
the simultaneous analysis of all the genes studied from
small amounts of tissue. Functional assays of procoagu-
lant activity (PCA) and TF activity were also performed on
these tissues. Evidence of ongoing coagulation was
sought in arthritic mice by measuring the plasma concen-
tration of TAT.
Materials and methods
Induction of AIA
C57Bl/6 mice (Iffa-Credo, L’Arbresle, France) between 8
and 10 weeks old were immunized at day 0 and 7 with
100 mg of methylated bovine serum albumin (Sigma
Chemical Company, Buchs, Switzerland) emulsified in
0.1 ml Freund’s complete adjuvant containing 200 mg
mycobacterial strain H37RA (Difco, Basel, Switzerland) by
intradermal injection at the base of the tail. On the same
day, 2 ×109 heat-killed  Bordetella pertussis organisms
(Berna, Bern, Switzerland) were injected intraperitoneally
as additional adjuvant. Arthritis was induced at day 21 by
intra-articular injection of 100 mg of methylated bovine
serum albumin in 10 ml sterile phosphate-buffered saline
solution (PBS) into the right knee, the left knee being
injected with sterile PBS alone. Institutional approval was
obtained for these experiments.
Induction of CIA
Male DBA/1J mice between 8 and 10 weeks of age were
obtained from BRL/RCC Biotechnology & Animal Breed-
ing (Füllinsdorf, Switzerland). Native chicken type II colla-
gen (MM Griffith, Salt Lake City, UT, USA) was dissolved
in 0.1 M acetic acid overnight at 2 mg/ml. Collagen
(100 mg) emulsified in Freund’s complete adjuvant con-
taining 5 mg/ml Mycobacterium tuberculosis was injected
intradermally at the base of the tail. At day 24 after the first
injection, a booster injection of 100 mg of native chicken
collagen in Freund’s incomplete adjuvant was given intra-
dermally at the base of the tail. All immunization reagents
were purchased from DIFCO (Basel, Switzerland). Clinical
assesment of arthritis was performed in accordance with
established protocols [22].
RNA extraction
Cryostat sections of synovial tissues from knee joints (AIA
model) or cryostat sections of total paws (CIA model)
were homogenized in Trizol reagent (Gibco BRL, Berne,
Switzerland) and total RNA extractions were performed in
accordance with the manufacturer’s instructions.
DNA template set preparation for RNase protection assay
(RPA)
Complementary DNA (cDNA) fragments of a different size
for each of the chosen genes were recovered by reverse
transcriptase-polymerase chain reaction (RT-PCR) and sub-
sequently subcloned into the pGEM-T plasmid (Promega,
Wallisen, Switzerland). Positive clones with antisense orien-
tation with respect to the T7 promoter were identified by
colony polymerase chain reaction (PCR) and then their
complete sequence was verified by DNA sequencing. Table
1 summarizes the details for each probe.
Probe labeling and RPA
Radioactive multiriboprobe preparation and RPA were per-
formed in accordance with standard protocols. Briefly, anti-http://arthritis-research.com/content/2/6/504
sense a32P-UTP-labeled riboprobes were synthesized by
transcription in vitro of the DNA template set, which con-
tained all the linearized plasmid cDNAs pooled in equimolar
amounts. DNase I treatment was performed to remove the
DNA templates and riboprobes were purified by
phenol/chloroform extraction followed by ethanol precipita-
tion using glycogen as carrier. For each sample, about 5 mg
of total RNA was hybridized overnight at 52°C with 3 ×105
cpm of the labeled multiprobe. Samples were first treated
with an RNase cocktail (Ambion, Austin, TX, USA); RNase
was then removed by treatment with proteinase K and
samples were purified by extraction in phenol/chloroform
followed by ethanol precipitation using glycogen as carrier.
Protected fragments were resolved through a 5% sequenc-
ing gel. Precise quantification of all the experimental
samples for all time points studied was determined by ana-
lyzing the gels with an InstantImager apparatus and soft-
ware (Packard Instruments, Berne, Switzerland). For each
protected band analyzed, a cpm/mm2 value was obtained.
This value was corrected for sample-loading errors by nor-
malizing with the respective cpm/mm2 value calculated for
the constitutively expressed glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) gene, which was also included in
the template set. Ratio values between arthritic/nonarthritic
joints were then calculated for each time point.
Preparation of tissue extracts
Tissue extracts were prepared from cryostat sections (see
RNA preparation above) as described before [4].
Measurement of procoagulant activity and TF activity
PCA was measured in tissue extracts from knee joints of
mice with AIA or from paws of mice with CIA by a modi-
fied one-stage clotting assay. Briefly, tissue extracts
(25 ml) were mixed with an equal volume of phospholipids
(Dade-Behring, Düdingen, Switzerland). After adding 50 ml
rabbit citrated plasma and 50 ml 0.02 M calcium chloride,
time to thrombus formation was recorded using a micro-
coagulometer (Dialine, Itingen, Switzerland). TF activity in
tissue extracts was measured using a commercially avail-
able kit (American Diagnostica, Greenwich, CT, USA).
Determination of thrombin–antithrombin III
Citrated plasmas were obtained from arthritic and
nonarthritic mice. Thrombin–antithrombin III (TAT) concen-
tration in plasma was measured using a commercially
available ELISA (enzyme-linked immunosorbent assay) kit
designed for human TAT (Enzygnost TAT, Dade-Behring,
Düdingen, Switzerland), which cross-reacts also with
murine TAT. The concentration of murine TAT was calcu-
lated according to the human TAT standard curve.
Statistical analysis
The unpaired Student’s t-test was used to compare
means for normally distributed values. A level of P < 0.05
was considered statistically significant.
Results
Detection of gene expression by multiprobe RNAse
protection assay
A typical autoradiograph obtained with the multiprobe set
is shown in Fig. 1a. It reveals the expression of eight
probe-protected bands in RNA from mouse skin. The
actual size of each of the protected fragments corre-
sponded with their expected size (compare with Table 1).
Confirmation of multiprobe specificity
To confirm the specificity of the bands detected, we ana-
lyzed RNA samples that either lacked a particular mRNA
species or over- or under-expressed it.
In Fig. 1b, the patterns of the protected fragments
detected in RNAs prepared from PAI1, UPA, and PAR1
knockout mice were compared with those prepared from
wild-type mice. As expected, no PAI1, UPA, or PAR1 pro-
tected bands were detected in kidney RNA from the
respective deficient mice. For TF, TFPI, and EGR1, we
analyzed kidney RNA from lipopolysaccharide-treated
mice (Fig. 1c), which confirmed the upregulation of TF and
EGR1 upon lipopolysaccharide treatment, while TFPI was
downregulated [23]. For VEGF, we observed its striking
upregulation in hypoxic endothelial cells using the multi-
probe assay, whereas the mRNA was not detected in nor-
moxic cells (Fig. 1d).
Synovial expression of procoagulant and fibrinolytic genes
in AIA
Total RNAs were extracted from dissected synovial
tissues of arthritic and nonarthritic joints (injected with
PBS) at various time points (2, 4, and 16 h, and 3, 7, and
14 d) after AIA induction. A representative multiprobe
assay autoradiograph showing the mRNA expression at
4 h and at 7 d in the arthritic and nonarthritic knees is
shown in Fig. 2. As early as 4 h after AIA induction, there
was a clear-cut upregulation of all the genes except VEGF
in the arthritic (right) knee as compared with the unin-
volved (left) knee. At  7 d after AIA induction, although
increased expression of TF and PAI1 mRNA was still
evident in the arthritic joint, the increased expression of
the other mRNA species was less marked than before.
Analysis of the whole time course of expression yielded
four major observations (Fig. 3):
1) PAR1, TFPI, EGR1, and UPA showed a rapid initial
increase of mRNA levels, which peaked between 2
and 4 h, followed by a sharp decrease to near basal
levels at 16 h.
2) The kinetics of PAI1 and TF induction differed from that
of the other genes studied. PAI1 reached its peak level (a
3.5-fold increase in comparison with the control knee) at
16 h, followed by a slow decrease, so that the level was
twofold by day 7 and 1.5-fold by day 14. TF expression
increased gradually, peaking (to more than threefold) by
day 7, and remaining at more than twofold by day 14.3) At day 14, expression of TF, PAI1, and UPA was still
increased (to about 1.4-fold each).
4) VEGF expression hardly changed during the experiment.
Increased expression of procoagulant and fibrinolytic
genes changes in collagen-induced arthritis
The expression of the same genes during CIA was ana-
lyzed using the same multiprobe set. RNA samples from
arthritic paws of collagen-immunized mice were compared
with samples from nonimmunized control mice. For this
Arthritis Research    Vol 2 No 6 Salvi et al
Figure 1
RNase protection assay with the set of coagulation/fibrinolytic genes. (a) Typical eight-band protection pattern resulting from the analysis of 5 mg
of mouse-skin total RNA. (b) Kidney RNA prepared from various knockout (KO) mice (PAI1-,  UPA-, or PAR1-deficient mice) and from wild-type
(WT) mice, analyzed using RPA. (c) Kidney RNA prepared from lipopolysaccharide (LPS)-treated or untreated mice, analyzed using RPA. (d) RNA
from murine hypoxic or normal endothelial cells, analyzed using RPA. In all these RPA experiments, 5 mg of total RNA/lane was analyzed.
Table 1
Probes used in the multiprobe RPA set
Gene Gene-bank  Sequence  Protected 
template accession number chosen, nt probe, nt
PAR1 L03529 881–1280 400
TFPI AF004833 781–1090 310
TF M57896 655–940 286
EGR1 M20157 1581–1840 260
VEGF M95200 436–650 215
UPA X02389 1154–1354 201
PAI1 M33960 1151–1330 180
GAPDH M32599 944–1050 107
nt, nucleotides.
Figure 2
Synovial levels of mRNA from procoagulant and fibrinolytic genes in
AIA, as analyzed by RPA. (a) Autoradiographic signals of synovial RNA
samples from left (L; control) and right (R) knees, 4 h after arthritis
induction. The single sample shown for each condition shows the
typical, reproducible pattern obtained from the RPA analysis of at least
three different RNAs, each from different animals. (b) Same as (a), but
7 d after arthritis induction.experiment, we used only one time point. Animals were
sacrified 42 d after the first immunization, when the inci-
dence of arthritis reaches >80% and the severity, as eval-
uated by clinical scores, is maximal.
Figure 4a shows a representative autoradiograph demon-
strating the upregulation of all the genes assayed in the
arthritic paw in comparison with the control paw. TF and
PAI1 had the highest increases – about fourfold and
about threefold, respectively (Fig. 4b). All the other genes
showed an approximately twofold increase over controls.
Increased procoagulant and TF activity in arthritic joints
Since the pattern of mRNA modulation observed in AIA
and CIA strongly suggested a shift of the coagulation/fibri-
nolytic balance in favor of coagulation during joint inflam-
mation, we next tried to confirm this prediction at a
functional level. We first compared PCA in tissue extracts
prepared from arthritic and nonarthritic joints (Fig. 5a).
Time to reach thrombus formation was decreased in
arthritic joints in both models (by 24% in CIA, and by 72%
in AIA), although only the decrease in AIA was statistically
significant. Because increased PCA in arthritic joints
could result from increased TF activity, we also studied TF
activity in these samples (Fig. 5b). It was increased in both
models (by 78% in CIA, and by 365% in AIA), but only the
increase in AIA was statistically significant.
Increased plasma TAT levels in arthritic mice
Because TAT is considered to be an indicator of ongoing
activation of the clotting system, we measured its concen-
tration in the plasma of arthritic mice. We found a statisti-
cally significant increase of TAT in the plasma of CIA
animals (3.5 times its concentration in nonarthritic mice)
but only a very modest increase (by 27%; not statistically
significant) in AIA (Fig. 5c).
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Figure 3
Time course of accumulation of mRNA from procoagulant and fibrinolytic genes during AIA. RNA levels are expressed as arthritic/normal knee
value ratios, after correcting for GAPDH signal. The 0 time point is given the value 1. Values are the mean ± SEM of at least three different mRNA
values from three different mice.Discussion
Excessive fibrin deposition has been shown to be deleteri-
ous in inflammation associated with various diseases such
as hypoxia, sepsis, and RA [24,25]. Because the molecu-
lar mechanisms underlying fibrin deposition in RA have not
been elucidated, we have characterized the alteration in
coagulation and fibrinolytic gene expression in two murine
models of RA. By analyzing the kinetics of gene expres-
sion in the AIA model, we were able to sample the very
early phases of synovial inflammation. To extend our
observations, we then analyzed total paw RNA prepared
from CIA mice. In this model, synovial fibrin is also present
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Figure 4
RNA from procoagulant and fibrinolytic genes in paws of mice with CIA, as analyzed by RPA. (a) Autoradiographic signals of RNA samples from
either arthritic paws (CIA) or normal paws from nonimmunized (NI) animals. The single sample shown for each condition represents the typical,
reproducible pattern obtained from the RPA analysis of four RNAs, each from a different animal. (b) Expression of genes studied during CIA,
shown as the ratio of mRNA in arthritic to that in normal paws (CIA/NI), after correction for GAPDH signal. Values are means ± SEM of at least four
different mRNA values from four different mice. *P<0.05, CIA versus NI values.
Figure 5
Activity of procoagulant and TF and concentrations of plasma TAT in mice with induced arthritis (CIA or AIA) and controls. (a) PCA (expressed in
seconds taken for thrombus formation) in tissue extracts. Arthritic tissue extracts (A) were prepared from arthritic, swollen paws at day 42 after the
first immunization (CIA model) or from arthritic right knee joints at day 3 after arthritis induction (AIA model). Nonarthritic (NA) tissue extracts were
from paws of normal, nonimmunized mice (CIA model) or normal left knees (contralateral to induced arthritis; AIA model). (b) TF activity in arthritic
(A) and nonarthritic (NA) tissue extracts (the same extracts as were used for PCA), measured using a chromogenic assay. (c) Plasma
concentrations of TAT complexes as determined in arthritic (A) mice in comparison with nonimmunized, nonarthritic (NA) controls. Citrated plasmas
from arthritic mice were prepared at day 42 after the first immunization (CIA model) or at day 3 after arthritis induction (AIA model). Values are
means ± SEM of at least four samples from four mice. *P<0.05, arthritic versus nonarthritic values.and has a deleterious role in inflammation (Marty et al,
submitted). In CIA, we studied gene expression at 42 d
after immunization, when inflammation is clinically active.
One possible drawback of using total paw RNA is that
paws contain tissues in addition to synovia. Nevertheless,
the use of total paw RNA has been shown to accurately
reflect synovial RNA changes of cytokine levels in CIA [26].
An upregulation of both procoagulant and fibrinolytic
genes was observed in both models. The pattern of
expression in CIA at day 42 approximated that at the early
time points in AIA, with TF and PAI1 showing the most
significant increases. If the protein expression of these
molecules parallels their transcription, then the combined
increase of TF and PAI-1 would favor fibrin formation and
its persistence in the joint.
The transcriptional regulation of the changes noted are not
completely understood. The increases in TF, PAI-1, and
uPA are most likely to be due to the increased secretion of
cytokines such as IL-1 and TNF-a, which are known induc-
ers of these genes and whose presence in the synovium in
AIA has been documented by other workers [27]. The
transcriptional regulation of the TF gene probably involves
activation of the transcription factor nuclear factor kB
(NF-kB). Indeed, an enhancer in the TF gene containing
an NF-kB site that is activated by endotoxin, TNF-a, and
IL-1 has been found [28]. Moreover, findings in a recent
study [29] suggest that induced TF and PAI1 expression
by vascular smooth muscle and endothelial cells may be
simultaneously mediated by activation of NF-kB. In addi-
tion, TF expression is under the control of another proximal
enhancer [28], containing overlapping binding sites for the
constitutively expressed SP1 and the inducible EGR1
transcription factor. The early rise of EGR1 expression in
AIA, at 2 to 4 h, is consistent with the immediate-early
gene expression pattern of this gene and may be responsi-
ble for the induction of early expression of TF. However,
by day 3, EGR1 expression had declined to control levels,
while  TF expression remained elevated, an observation
suggesting that EGR1 does not contribute to the sus-
tained overexpression of TF in AIA synovial tissues. Tran-
sient PAR1 overexpression can also contribute to the early
stimulation of TF [13]. VEGF expression remained essen-
tially unchanged throughout the progression of AIA, with
only a slight increase at the late time points. In CIA there
was only a slight, not significant, increase of VEGF mRNA
levels. This is somewhat surprising, in view of data showing
increased expression in RA [17].
We found significantly increased functional coagulation
activity in the AIA model but only a slight, nonsignificant
increase in the CIA model. TF activity in AIA can be totally
accounted for by changes in TF mRNA. By contrast, the
discrepancy between TF activity and TF mRNA levels in
CIA needs to be clarified. Furthermore, we were able to
demonstrate increased plasma TAT levels in both models,
though the difference was more striking in CIA than in AIA.
Plasma TAT levels result most probably from the spillover
into the systemic circulation of TAT that originated in
arthritic joints. As multiple joints are affected in CIA, but
only one in AIA, one could expect TAT values to be more
elevated in CIA than in AIA. Altogether, these findings
support the conclusion that articular inflammation is
accompanied by significant upregulation of molecules that
favor increased extravascular coagulation activity and
fibrin deposition.
In conclusion, we have found that experimental arthritis is
associated with a pronounced upregulation of both pro-
coagulation and fibrinolytic genes, that in its later stages
tends to favor the formation and persistence of fibrin.
Workers using mice with targeted disruptions of either the
fibrinogen gene and/or genes of the fibrinolytic pathway
have observed that fibrin persistence may delay wound
healing [30] and exacerbate progression of atherosclero-
sis [31], glomerulonephritis [32], and arthritis [4]. In the
latter case, if efficient fibrinolytic mechanisms are not suffi-
ciently activated in the course of joint inflammation, the
persistence of joint fibrin may contribute to continued syn-
ovitis and subsequent joint damage.
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